Diabetes Research and Clinical Practice
Volume 90, Issue 2 , Pages 182-190 , November 2010

Safety and tolerability of vildagliptin vs. thiazolidinedione as add-on to metformin in type 2 diabetic patients with and without mild renal impairment: A retrospective analysis of the GALIANT study

  • M.A. Banerji

      Affiliations

    • SUNY Health Science Center, Brooklyn, NY, USA
    • ,
  • D. Purkayastha

      Affiliations

    • Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
    • ,
  • B.H. Francis

      Affiliations

    • Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
    • Corresponding Author InformationCorresponding author at: Novartis Pharmaceuticals Corporation, One Health Plaza, Bldg. 501-Room 336, East Hanover, NJ 07936-1080, USA. Tel.: +1 862 7788337; fax: +1 862 7782345.

Received 11 March 2010 ,Revised 14 June 2010 ,Accepted 17 June 2010.

References 

  1. United States Renal Data System . USRDS 2007 Annual Data Report. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, US Department of Health and Human Services; 2007;
  2. National Institute of Diabetes and Digestive and Kidney Diseases . National Diabetes Statistics, 2007. Bethesda, MD: National Institutes of Health, US Department of Health and Human Services; 2008;
  3. Ahrén B, Landin-Olsson M, Jansson P-A, Svenson M, Holmes D, Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab. 2004;89:2078–2084
  4. Mari A, Sallas WM, He YL, Watson C, Ligueros-Saylan M, Dunning BE, et al. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed β-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab. 2005;90:4888–4894
  5. He Y-L, Sadler MB, Sabo R, Balez S, Wang Y, Howard D, et al. The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers. Clin Pharmacokinet. 2007;46(9):787–802
  6. Dejager S, Razac S, Foley JE, Schweizer A. Vildagliptin in drug-naive patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm Metab Res. 2007;39:218–223
  7. Rosenstock J, Baron MA, Dejager S, Mills D, Schweizer A. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care. 2007;30:217–223
  8. Schweizer A, Couturier A, Foley JE, Dejager S. Comparison between vildagliptin and metformin to sustain reductions in HbA1c over one year in drug-naive patients with type 2 diabetes. Diabet Med. 2007;24:955–961
  9. Pi-Sunyer FX, Schweizer A, Mills D, Dejager S. Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Res Clin Pract. 2007;76:132–138
  10. Garber AJ, Schweizer A, Baron MA, Rochotte E, Dejager S. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab. 2007;9:166–174
  11. Bosi E, Camisasca RP, Collober C, Garber AJ. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care. 2007;30:890–893
  12. Rosenstock J, Baron MA, Camisasca RP, Cressier F, Couturier A, Dejager S. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared to component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab. 2007;9:175–185
  13. Ahrén B, Gomis R, Standl E, Mills D, Schweizer A. Twelve- and 52-week efficacy of the dipeptidyl peptidase-IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care. 2004;27:2874–2880
  14. Pratley RE, Rosenstock J, Pi-Sunyer FX, Banerji MA, Schweizer A, Couturier A, et al. Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care. 2007;30(12):3017
  15. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2008;31:173–175
  16. Stumvoll M, Haring H-U. Glitazones: clinical effects and molecular mechanisms. Ann Med. 2002;34:217–224
  17. Agrawal A, Sautter MC, Jones NP. Effects of rosiglitazone maleate when added to a sulfonylurea regimen in patients with type 2 diabetes mellitus and mild to moderate renal impairment: a post hoc analysis. Clin Ther. 2003;25(11):1764–2754
  18. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation. 2003;108:2941–2948
  19. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355:2427–2443
  20. Masakazu H, Akizuki M. Which hypoglycemic agents to use in type 2 diabetic subjects with CKD and how?. Nephrol Dial Transplant. 2009;24(2):338–341
  21. Blonde L, Dagogo-Jack S, Banerji MA, Pratley RE, Marcellari A, Braceras R, et al. Vildagliptin is as effective as thiazolidinediones as add-on therapy in patients failing on metformin: results of the GALIANT trial – a primary care, type 2 diabetes study. Diabetes Obes Metab. 2009;11:978–986
  22. Rigalleau V, Lasseur C, Perlemoine C, Barthe N, Raffaitin C, Liu C, et al. Estimation of glomerular filtration rate in diabetic subjects: Cockcroft formula or modification of diet in renal disease study equation?. Diabetes Care. 2005;28(4):838–843
  23. Williams-Herman D, Round E, Swern SA, Musser B, Davies JM, Stein PP, et al. Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis. BMC Endocr Disord. 2008;8:14
  24. Bolli G, Dotta F, Rochotte E, Cohen SE. Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study. Diabetes Obes Metab. 2008;10(1):82–90
  25. Filozof C, Schwartz S, Foley JE. Effect of vildagliptin as add-on therapy to a low-dose metformin. World J Diabetes. 2010;1(1):19–26
  26. Schweizer A, Dejager S, Bosi E. Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week double-blind, randomized trial. Diabetes Obes Metab. 2009;11:804–812
  27. Charbonnel BH, Matthews DR, Schernthaner G, Hanefeld M, Brunetti P QUARTET Study Group. A long-term comparison of pioglitazone and gliclazide in patients with type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial. Diabet Med. 2005;22:399–405
  28. Matthews DR, Charbonnel BH, Hanefeld M, Brunetti P, Schernthaner G. Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes Metab Res Rev. 2005;21:167–174
  29. Ligueros-Saylan M, Foley JE, Schweizer A, Couturier A, Kothny W. An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials. Diabetes Obes Metab. 2010;12(6):495–509
  30. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007;298:194–206
  31. Arem R. Hypoglycemia associated with renal failure. Endocrinol Metab Clin North Am. 1989;18:103–121
  32. Fischer JA, Lees JH, Newman . Hypoglycemia in hospitalized patients. Causes and outcomes. N Engl J Med. 1986;315:1245–1250

PII: S0168-8227(10)00324-4

doi: 10.1016/j.diabres.2010.06.022

Diabetes Research and Clinical Practice
Volume 90, Issue 2 , Pages 182-190 , November 2010

Article Tools

* Image Usage & Resolution